Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts
- PMID: 34362815
- PMCID: PMC8740940
- DOI: 10.2337/dc21-0226
Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts
Abstract
Objective: To assess the progression of type 1 diabetes using time to peak glucose or C-peptide during oral glucose tolerance tests (OGTTs) in autoantibody-positive relatives of people with type 1 diabetes.
Research design and methods: We examined 2-h OGTTs of participants in the Diabetes Prevention Trial Type 1 (DPT-1) and TrialNet Pathway to Prevention (PTP) studies. We included 706 DPT-1 participants (mean ± SD age, 13.84 ± 9.53 years; BMI Z-score, 0.33 ± 1.07; 56.1% male) and 3,720 PTP participants (age, 16.01 ± 12.33 years; BMI Z-score, 0.66 ± 1.3; 49.7% male). Log-rank testing and Cox regression analyses with adjustments (age, sex, race, BMI Z-score, HOMA-insulin resistance, and peak glucose/C-peptide levels, respectively) were performed.
Results: In each of DPT-1 and PTP, higher 5-year diabetes progression risk was seen in those with time to peak glucose >30 min and time to peak C-peptide >60 min (P < 0.001 for all groups), before and after adjustments. In models examining strength of association with diabetes development, associations were greater for time to peak C-peptide versus peak C-peptide value (DPT-1: χ2 = 25.76 vs. χ2 = 8.62; PTP: χ2 = 149.19 vs. χ2 = 79.98; all P < 0.001). Changes in the percentage of individuals with delayed glucose and/or C-peptide peaks were noted over time.
Conclusions: In two independent at-risk populations, we show that those with delayed OGTT peak times for glucose or C-peptide are at higher risk of diabetes development within 5 years, independent of peak levels. Moreover, time to peak C-peptide appears more predictive than the peak level, suggesting its potential use as a specific biomarker for diabetes progression.
© 2021 by the American Diabetes Association.
Figures

References
-
- Sosenko JM, Palmer JP, Greenbaum CJ, et al. . Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006;29:643–649 - PubMed
-
- Vardi P, Crisa L, Jackson RA. Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia 1991;34:93–102 - PubMed
-
- Chase HP, Voss MA, Butler-Simon N, Hoops S, O’Brien D, Dobersen MJ. Diagnosis of pre-type I diabetes. J Pediatr 1987;111:807–812 - PubMed
-
- Srikanta S, Ganda OP, Rabizadeh A, Soeldner JS, Eisenbarth GS. First-degree relatives of patients with type I diabetes mellitus—islet-cell antibodies and abnormal insulin secretion. N Engl J Med 1985;313:461–464 - PubMed
-
- Knip M, Vähäsalo P, Karjalainen J, Lounamaa R; Childhood Diabetes in Finland Study Group . Natural history of preclinical IDDM in high risk siblings. Diabetologia 1994;37:388–393 - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- U01 DK085476/DK/NIDDK NIH HHS/United States
- R01 DK127308/DK/NIDDK NIH HHS/United States
- U01 DK061010/DK/NIDDK NIH HHS/United States
- U01 DK106993/DK/NIDDK NIH HHS/United States
- P30 DK097512/DK/NIDDK NIH HHS/United States
- U01 DK103282/DK/NIDDK NIH HHS/United States
- U01 DK061042/DK/NIDDK NIH HHS/United States
- U01 DK085509/DK/NIDDK NIH HHS/United States
- UC4 DK117009/DK/NIDDK NIH HHS/United States
- U01 DK127786/DK/NIDDK NIH HHS/United States
- U01 DK085466/DK/NIDDK NIH HHS/United States
- U01 DK103153/DK/NIDDK NIH HHS/United States
- U01 DK061058/DK/NIDDK NIH HHS/United States
- UL1 TR002529/TR/NCATS NIH HHS/United States
- U01 DK085453/DK/NIDDK NIH HHS/United States
- R01 DK121843/DK/NIDDK NIH HHS/United States
- R01 DK124395/DK/NIDDK NIH HHS/United States
- U01 DK106984/DK/NIDDK NIH HHS/United States
- U01 DK085499/DK/NIDDK NIH HHS/United States
- U01 DK107013/DK/NIDDK NIH HHS/United States
- U01 DK103266/DK/NIDDK NIH HHS/United States
- UC4 DK106993/DK/NIDDK NIH HHS/United States
- P30 DK045735/DK/NIDDK NIH HHS/United States
- KL2 TR002530/TR/NCATS NIH HHS/United States
- U01 DK107014/DK/NIDDK NIH HHS/United States
- U01 DK106994/DK/NIDDK NIH HHS/United States
- U01 DK061034/DK/NIDDK NIH HHS/United States
- U01 DK085461/DK/NIDDK NIH HHS/United States
- U01 DK103180/DK/NIDDK NIH HHS/United States
- U01 DK085465/DK/NIDDK NIH HHS/United States
- U01 DK085504/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical